💼 Elanco Hiring: Pharmacovigilance Analyst (R&D) – Freshers | Bangalore | 0–1 Year Exp
📍 Location: Bangalore, India
🎓 Eligibility: B.Pharm, M.Pharm, Pharm.D, MSc, BSc, Life Sciences, Veterinary
🧪 Experience: 0 – 1 Year
💰 Salary: Competitive (Industry Standard)
📝 Job Type: Pharmacovigilance Analyst (R&D) | Full-Time | PV Case Processing
🔎 Verified: ✅ Verified Job via Medical Jobs India – hitechplus.in
📄 Job Overview
Elanco (NYSE: ELAN), a global leader in animal health, is hiring Pharmacovigilance Analysts (R&D) in Bangalore. Freshers passionate about improving animal lives and building a career in PV can gain hands-on experience in adverse event case processing and regulatory compliance.
🔬 Key Responsibilities
- ✔ Perform data entry, seriousness, and causality assessment of adverse event reports.
- ✔ Identify case processing issues and escalate delays to management.
- ✔ Ensure compliance with global pharmacovigilance regulations.
- ✔ Collaborate with internal and external stakeholders to maintain case quality.
- ✔ Support adverse event and product complaint submissions within timelines.
✅ Required Qualifications & Skills
- ✅ Bachelor’s or Master’s degree in Pharmacy, Life Sciences, or Veterinary.
- ✅ 0–1 year of experience in pharmacovigilance or related fields.
- ✅ Basic knowledge of medical terminologies and adverse event reporting.
- ✅ Strong communication and multitasking abilities.
- ✅ Knowledge of global and local regulatory requirements is a plus.
🎁 Benefits of Joining Elanco
- 🌍 Work with a global leader in animal health.
- 📈 Learning and growth in pharmacovigilance and R&D.
- 💼 Competitive salary and performance incentives.
- 🤝 Inclusive, diverse, and innovation-driven workplace.
For more Job 👇👇
📌 Note Before You Apply:
Update your CV to highlight pharmacovigilance knowledge, AE case processing, and R&D experience for better selection chances.
👇 Apply Link Will Be Visible in 15 Seconds 👇
🟢 Verified Job via Medical Jobs India – hitechplus.in
 | Animal Health PV Jobs Bangalore | 0–1 Year Exp){kind=link}
0 Comments